ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 1481

Safety of Secukinumab in Patients with Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis and Hidradenitis Suppurativa: Updated Pooled Data from 69 Clinical Trials
Abstract Number: 1482

Predictors of Clinical Response to Intravenous Secukinumab Among Patients with Axial Spondyloarthritis: A Post Hoc Analysis of a Phase 3 Trial
Abstract Number: 1483

Real World Data on Infections from the Indian SLE Inception Cohort for Research (INSPIRE): Spectrum and Risk Factors
Abstract Number: 1484

A Retrospective Evaluation of Glucagon-like Peptide-1 Receptor Agonists in SLE Patients
Abstract Number: 1485

Genetic Contributions to Systemic Lupus Erythematosus: Concordance Rates in California Twins
Abstract Number: 1486

Cardiovascular Risk in Systemic Lupus Erythematosus: Carotid Ultrasonography Is Useful for the Re-stratification of Cardiovascular Risk Determined by Score2
Abstract Number: 1487

Pregnancy Outcome and Risk Factors Analysis in Patients with Systemic Lupus Erythematosus Complicated with Thrombocytopenia
Abstract Number: 1488

Clinical Utility and Performance of Anti-C1q Antibodies for Systemic Lupus Erythematosus: Comparative Analysis of Three Different Assays
Abstract Number: 1489

Lupus Nephritis Clinical and Serological Responses at 12 Months: Implications for Repeat Biopsy, Intensified Immunosuppression or Additional Anti-proteinuric Therapy
Abstract Number: 1490

Multi-centered Clinical Validation of T Cell-bound C4d (TC4d) and T Cell Autoantibodies (TIgG and TIgM): Sensitive and Specific Biomarkers of SLE with Enhanced Accuracy Compared to Conventional SLE Tests
Abstract Number: 1491

Self-Reported Cognitive Function Among Older Adults with Systemic Lupus Erythematosus (SLE) Compared to Older Adults with Other Rheumatic and Musculoskeletal Conditions
Abstract Number: 1492

Timing of SLEDAI-2K Item Improvements During the First Year of Intravenous Anifrolumab Treatment of Moderate to Severe SLE
Abstract Number: 1493

How Do Lupus Nephritis Patients Who Achieve Renal Remission Fare? A 3-year Comparison in Terms of GFR Decline
Abstract Number: 1494

Trajectories of Disease Evolution upon Treatment Initiation in Systemic Lupus Erythematosus: Pooled Results from Three Randomized Clinical Trials of Belimumab
Abstract Number: 1495

Real-World Reduction in Disease Flares and Oral Corticosteroid Use with Anifrolumab Therapy in Systemic Lupus Erythematosus: A Claims-Based Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].